Search bioRxiv⌕ Search

bioRxiv · 10.1101/2020.05.27.119016

Personalized logical models to investigate cancer response to BRAF treatments in melanomas and colorectal cancers

Abstract

The study of response to cancer treatments has benefited greatly from the contribution of different omics data but their interpretation is sometimes difficult. Some mathematical models based on prior biological knowledge of signalling pathways, facilitate this interpretation but often require fitting of their parameters using perturbation data. We propose a more qualitative mechanistic approach, based on logical formalism and on the sole mapping and interpretation of omics data, and able to recover differences in sensitivity to gene inhibition without model training. This approach is showcased by the study of BRAF inhibition in patients with melanomas and colorectal cancers who experience significant differences in sensitivity despite similar omics profiles. We first gather information from literature and build a logical model summarizing the regulatory network of the mitogen-activated protein kinase (MAPK) pathway surrounding BRAF, with factors involved in the BRAF inhibition resistance mechanisms. The relevance of this model is verified by automatically assessing that it qualitatively reproduces response or resistance behaviours identified in the literature. Data from over 100 melanoma and colorectal cancer cell lines are then used to validate the models ability to explain differences in sensitivity. This generic model is transformed into personalized cell line-specific logical models by integrating the omics information of the cell lines as constraints of the model. The use of mutations alone allows personalized models to correlate significantly with experimental sensitivities to BRAF inhibition, both from drug and CRISPR targeting, and even better with the joint use of mutations and RNA, supporting multi-omics mechanistic models. A comparison of these untrained models with learning approaches highlights similarities in interpretation and complementarity depending on the size of the datasets. This parsimonious pipeline, which can easily be extended to other biological questions, makes it possible to explore the mechanistic causes of the response to treatment, on an individualized basis. Author summaryWe constructed a logical model to study, from a dynamical perspective, the differences between melanomas and colorectal cancers that share the same BRAF mutations but exhibit different sensitivities to anti-BRAF treatments. The model was built from the literature and completed from existing pathway databases. The model encompasses the key proteins of the MAPK pathway and was made specific to each cancer cell line (100 melanoma and colorectal cell lines from public database) using available omics data, including mutations and RNAseq data. It can simulate the effect of drugs and show high correlation with experimental results. Moreover, the structure of the network confirms both the importance of the reactivation of the MAPK pathway through CRAF and the involvement of PI3K/AKT pathway in the mechanisms of resistance to BRAF inhibition. The study shows that, because of the low number of samples, the mechanistic approach that we propose provides different insights than powerful standard machine learning methodologies would, showing the complementarity between the two approaches. An important aspect to mention is that the mechanistic approach presented here does not rely on training datasets but directly interprets and maps data on the model to simulate drug responses.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Beal, J., Pantolini, L., Noël, V., Barillot, E., Calzone, L.. 2020-05-27. Personalized logical models to investigate cancer response to BRAF treatments in melanomas and colorectal cancers. https://doi.org/10.1101/2020.05.27.119016

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

A single-cell transcriptomic atlas of the pigtail macaque lung

Background: The lungs undergo substantial physiological and immunological changes during respiratory illness to meet the host's increased metabolic and oxygen demands. These responses require coordination among epithelial, endothelial, stromal, and immune cells throughout the respiratory zone, interstitium, and vasculature. Nonhuman primates (NHPs) are a valuable model for studying pulmonary biology as they have similar anatomic, physiologic, and immunologic correspondence to humans. Despite the widespread use of NHPs in pulmonary research, the cellular diversity and molecular characteristics of the pigtail macaque lung remain incompletely defined. Methods: Parenchymal lung tissue from five adult female pigtail macaques (Macaca nemestrina) was dissociated into single cells and profiled using 10x Genomics 3' single-cell RNA sequencing (scRNA-Seq). Next, ambient RNA was removed and quality control analyses performed. Samples were then integrated using scVI and scANVI. Cell types were labeled after unsupervised clustering and subclustering, followed by manual annotation using canonical marker genes. We compared lineages and cell types with the Level 4 Human Lung Cell Atlas (HLCA) using scArches reference mapping and with the Rhesus Immune Reference Atlas (RIRA) using Seurat label transfer. Results: The atlas includes 61,323 cells representing 37 cell types in epithelial, mesenchymal, endothelial, lymphoid, and myeloid populations. Annotated populations included both major and rare lung cell types, including alveolar type I and II cells, club and multiciliated cells, aerocyte capillary, and lymphatic endothelial cells, pre-terminal bronchiole secretory cells, CD4+ and CD8+ T cells, and several innate-like lymphocyte populations (gamma delta T cells, MAIT-like cells, innate-like CD8+ T cells, and group 3 innate lymphoid cells). There was strong concordance at HLCA annotation level 4, including AT1 and AT2 cells (96% and 93%), B cells (94 to 97%), CD4+ T cells (99 to 100%), classical and non-classical monocytes (84% and 85%), alveolar macrophages (80%), and mast cells (96%). Immune populations mapped to the RIRA with similar fidelity (alveolar macrophages and B cells, 99%). Conclusions: While studies of pandemic respiratory infections, vaccines, and therapeutics rely on NHP disease models, this atlas provides a unique reference for epithelial, endothelial, stromal, and immune cell states in the pigtail macaque lung. We found that single-cell populations from the pigtail macaque lung are highly similar to those in the human lung at the lineage level. This reference will enable studies of pathogenesis and vaccine and drug efficacy in a highly translational model of the human lung.

systems biology↗

Cell cycling throttles epithelial--mesenchymal transition

Cell cycle phase is an understudied source of variation in gene expression. EMT is a case in point: this cell state transition that drives metastasis has been studied widely across tissue, stimulus, and microenvironmental conditions, yet cell cycle effects are routinely regressed out of single-cell EMT analyses. Here, we compare EMT between G1 and cycling (S/G2/M) cell states in two independent scRNA-seq datasets of TGF-{beta}-stimulated MCF10A mammary epithelial cells (varying dose and timepoint). G1 cells consistently show higher expression of EMT genes and upregulated RNA velocities than cycling cells, with the strongest upregulation in G1 EMT intermediate states. Consistent with the go-or-grow hypothesis, EMT and cell cycle programs inversely correlate; moreover, this anticorrelation extends to RNA velocity and strengthens with TGF-{beta} dose. We identify a 77-gene G1-specific EMT signature enriched for actin cytoskeletal and extracellular matrix genes that would otherwise be lost by regressing out cell cycle effects. This gene set prompts the hypothesis that, unconstrained by the cytoskeletal demands of mitosis, G1 cells have greater capacity to execute EMT. Further, we developed an EMT gene regulatory model coupled with a cell cycle module, and found through simulation that the model recapitulated this inverse EMT--cell cycle relationship. Using this model, we predict that cycle-selective chemotherapy enriches for the G1 intermediate state, which has high metastatic potential. Cell cycle phase thus ought not be regressed out of EMT states, given its influence on EMT.

systems biology↗

Multi-Enzyme Data-Independent Acquisition Mass Spectrometry for Proteoform-Aware Single-shot Proteomics

Biological regulation does not operate at the level of the protein but across ensembles of protein variants shaped by alternative splicing, post-translational modification and endogenous proteolytic processing. Yet most conventional bottom-up discovery proteomics workflows remain optimized for a canonical protein census, leaving much of the sequence-level variation invisible. Multi-enzyme digestion has been recognized as an effective strategy to expand sequence coverage and proteoform sensitivity, but existing implementations rely on resource-heavy per-enzyme liquid chromatography coupled to mass spectrometry (LC-MS) analysis, dedicated measurements for spectral library construction, and semi-manual reconciliation across multiple software tools, restricting the use to specialized laboratories and limited sample cohorts. Here we introduce mE-DIA, a multi-enzyme, proteoform-resolved data independent acquisition (DIA)-MS workflow that multiplexes complementary protease digested samples into a single DIA injection and processes them through a library-free pipeline within a single analysis engine, without supplemental data dependent acquisition (DDA)-MS measurements. The mE-DIA Pipeline graphical user interface orchestrates the analysis, and a dedicated proteoform inference algorithm and the interactive mE-DIA Peptide Mapper viewer make the sequence-level evidence explorable. Comparing the workflow to prevailing DDA-library-based multi-enzyme DIA on the same raw data and within shared search space showed increased identified protein groups by 30 % and protein groups quantified at [≤] 20 % CV by 47 %. A three-enzyme multiplex of the human pathogen Streptococcus pyogenes resolved 990 protein-backbone variants among 309 canonical protein entries, 1.8-fold more than the most productive single-enzyme analysis, including an H69 C-terminal proteoform of the ribosomal protein uS19 that the trypsin-only workflow did not resolve. By consolidating multi-enzyme acquisition, analysis and proteoform interpretation into one accessible toolset, mE-DIA brings sub-gene-resolved evidence within reach of routine single-shot discovery DIA proteomics.

systems biology↗